Why two vials of the same peptide are not the same material

Two vials sit on the bench. Same sequence, same catalogue number, same supplier, two different lot numbers. The label on each says 10 mg and 99% purity. A reasonable assumption is that they are interchangeable, and for a lot of work they are. But they are not the same material, and the ways they differ are the ways that quietly ruin an experiment you cannot afford to repeat.

Three numbers are involved, and they get collapsed into one on most spec sheets. Separating them is the whole of this article.

Purity, peptide content and counterion are three different measurements

Chromatographic purity is the fraction of UV-absorbing material eluting from the column that sits under your peak. It is an area percent, measured at a stated wavelength, under a stated gradient. It tells you how much of what came off the column was your compound relative to everything else the detector saw.

It does not tell you how much of the powder in the vial is peptide. That is net peptide content, and it is a separate assay — usually amino acid analysis or nitrogen determination. A lyophilised peptide is not pure peptide by mass. It is peptide, plus the counterion it was salted with, plus residual water it picked up during handling, plus whatever solvent survived lyophilisation.

The counterion is the third number, and it is the one most often left off entirely. Peptides purified by reversed-phase HPLC come off the column as trifluoroacetate salts, because TFA is the standard ion-pairing additive in the mobile phase. Depending on how many basic residues the sequence carries, TFA can account for a meaningful fraction of the dry mass. A vial labelled 10 mg, at 99% chromatographic purity, can contain appreciably less than 10 mg of peptide once counterion and water are subtracted — and the shortfall is not an error, it is arithmetic that the label never showed you.

Two lots of the same sequence, both honestly labelled 99%, can therefore differ in delivered peptide mass. If a downstream result scales with dose, that difference shows up as a potency difference between lots that has nothing to do with the peptide.

The counterion is a variable, not a footnote

TFA is not inert. Its role in peptide chemistry — as the acid in cleavage cocktails and as the ion-pairing agent in purification — means residual TFA is the default state of a synthetic peptide unless someone deliberately exchanged it. Salt form is not cosmetic: the counterion measurably changes the physicochemical behaviour of the resulting peptide material, and it is increasingly treated as a specified attribute rather than an incidental leftover of purification.^[1]

Practically, this matters in two situations. In cell work, residual trifluoroacetate is carried into the well along with the peptide, and it is not a neutral spectator at the concentrations that a high-salt lot can deliver. In any comparison between lots or between suppliers, a difference in salt form is a difference in what you actually pipetted, even when both certificates say the same purity.

The useful question to ask a supplier is not "is it pure" but "what salt is it, and what is the net peptide content". A supplier who can answer both is measuring the material. A supplier who can only answer the first is quoting a chromatogram.

The one percent that is not your peptide has an identity

A 99% pure peptide is 1% something else, and that something else is not random noise. Solid-phase synthesis produces a characteristic family of related impurities, and they are related to your target by construction — which is exactly why they are difficult to remove and why they often sit close to the main peak.

• Deletion sequences. A coupling step that does not go to completion leaves a chain missing one residue. The product is the target minus one amino acid: nearly the same mass, nearly the same hydrophobicity, and frequently eluting on the shoulder of the main peak rather than as a resolved impurity.
• Truncated and capped chains. Chains that stopped growing, or were capped to stop them growing, in order to prevent them re-entering the sequence later.
• Cyclisation and rearrangement products. Diketopiperazine formation at the dipeptide stage is a well-documented route to a specific impurity in the synthesis of therapeutic peptides, and it is a function of the sequence and the synthetic route rather than of sloppiness.^[2]
• Oxidation and deamidation products formed after synthesis, during storage or handling.

The reason to care about which of these is present, rather than only about the total, is that peptide-related impurities are not biologically silent by default. In the regulatory literature on synthetic peptides, impurity identity is treated as a question in its own right — with attention to whether a given related substance carries activity or immunogenic potential distinct from the parent compound.^[3] A 1% deletion sequence and a 1% oxidation product are the same number on a certificate and different materials in a well.

What this looks like in practice: two good lots

Lot A: synthesised on one route, purified to 98.6% area at 214 nm, TFA salt, net peptide content 81%, principal impurity a des-amino-acid deletion at position 4.

Lot B: same sequence, different route, purified to 98.9% at 214 nm, acetate salt, net peptide content 88%, principal impurity an oxidation product at a methionine.

Both certificates read ">98%". Neither supplier has done anything wrong. Reconstituted to the same nominal concentration, Lot B delivers roughly 9% more peptide per microlitre, carries a different counterion load into the medium, and brings a different related substance along with it. If your assay is sensitive, you will see a lot effect, and without the underlying numbers you will have no way to attribute it.

What a certificate has to show to be worth reading

• The chromatogram itself, not only the number derived from it — with the gradient, the column and the detection wavelength stated.
• Mass spectrometric identity, so that the peak being integrated is demonstrably the right molecule and not merely a peak.
• Net peptide content, and the method used to determine it.
• Counterion and salt form.
• Water content, since it drives the degradation chemistry once the vial is open.
• The lot number and the date of analysis, so the record can be tied to the vial in your hand.

A certificate that gives a purity figure and nothing else is not a measurement you can use. It is a claim, and it cannot be checked — which is the practical reason to keep the lot number for anything whose result you intend to rely on.

References

1. Impact of counterion and salt form on the properties of long-acting injectable peptide hydrogels for drug delivery. Faraday Discuss. 2025;260. PMID 40365687
2. Mechanistic Study of Diketopiperazine Formation during Solid-Phase Peptide Synthesis of Tirzepatide. ACS Omega. 2022;7(50):46809-46824. PMID 36570276
3. Assessing the immunogenicity risk of salmon calcitonin peptide impurities using in silico and in vitro methods. Front Pharmacol. 2024;15:1363139. PMID 39185315

This article describes the chemistry of peptide degradation and laboratory handling practice. It is not guidance for use in humans or animals. X Factor Peptides supplies research reference standards for in-vitro and non-clinical research only.